AK 002

Drug Profile

AK 002

Alternative Names: AK 002

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins University School of Medicine
  • Developer Allakos
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Mast cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Systemic mastocytosis
  • Preclinical Fibrosis

Most Recent Events

  • 15 Aug 2017 Allakos completes a phase I trial in healthy volunteers in Australia
  • 15 Aug 2017 Allakos completes a phase I trial in Systemic mastocytosis in Germany
  • 15 Aug 2017 Allakos plans a clinical programme for multi-indication in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top